The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)

Publications

Nawa H, Niimura T, Yagi K, Goda M, Zamami Y, Ishizawa K

Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments.

Cancer reports (Hoboken, N.J.) 2021 May 03;;e1402 — 2021 May 03 — e1402

Chen Y, Noma S, Taguchi Y, Takahashi M, Tsurutani J, Mori S, Sakaguchi S, Asou H, Tomii K

Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan.

Breast cancer (Tokyo, Japan) 2021 May;28;710-719 — 2021 May — 710-719

Jazieh KA, Budd GT, Dalpiaz N, Abraham J

Can CDK4/6 inhibitors cause fatal lung injury?

Expert review of anticancer therapy 2019 11;19;917-919 — 2019 11 — 917-919